Literature DB >> 23728346

Differential role of MyD88 and Mal/TIRAP in TLR2-mediated gastric tumourigenesis.

C L Kennedy1, M Najdovska1, H Tye1, L McLeod1, L Yu1, A Jarnicki2, P S Bhathal3, T Putoczki2, M Ernst2, B J Jenkins1.   

Abstract

Signalling by the toll-like receptor (TLR) family of pathogen recognition receptors has emerged as a key molecular component in the pathogenesis of an increasing number of inflammatory-related cancers, among which gastric cancer rates as the second most lethal cancer world-wide. The myeloid differentiation factor 88 (MyD88) adapter molecule has a critical role in mediating innate immune signalling by members of the TLR and interleukin (IL)-1 families, and has been associated with either pro- or antitumourigenic responses in various cancer models. However, little is known about the in vivo role of MyD88 adapter-like (Mal)/TIR-domain containing adapter protein (TIRAP), which is restricted to facilitating TLR4 and TLR2 signalling. To interrogate the role of these innate immune signalling components in gastric tumourigenesis, here we have employed the spontaneous gastric cancer gp130(F/F) mouse model, in which TLR2 promotes the growth of gastric tumours. Genetic ablation of Myd88 in gp130(F/F) mice suppressed tumourigenesis and was associated with increased apoptosis and reduced proliferation in the gastric tumour epithelium, comparable to that observed previously upon deletion of Tlr2 in gp130(F/F) mice. By contrast, the tumour burden in gp130(F/F):Mal(-/-) mice was equivalent to their gp130(F/F) littermates. At the molecular level, suppressed tumourigenesis in gp130(F/F):Myd88(-/-) mice correlated with reduced expression and activation of TLR2-regulated protumourigenic genes and signalling pathways, respectively. Consistent with the previously defined non-essential role for TLR2 in gastric tumour inflammation, the extent of inflammatory cell infiltrates in gastric tumours from gp130(F/F):Mal(-/-) and gp130(F/F):Myd88(-/-) mice remained unaltered compared with gp130(F/F) mice. Collectively, our data reveal a differential, but inflammation-independent, requirement for Mal and MyD88 during TLR2-promoted gastric tumourigenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23728346     DOI: 10.1038/onc.2013.205

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  21 in total

1.  Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma.

Authors:  A Miller; L McLeod; S Alhayyani; A Szczepny; D N Watkins; W Chen; P Enriori; W Ferlin; S Ruwanpura; B J Jenkins
Journal:  Oncogene       Date:  2016-11-28       Impact factor: 9.867

2.  Identification of a TLR2-regulated gene signature associated with tumor cell growth in gastric cancer.

Authors:  A C West; K Tang; H Tye; L Yu; N Deng; M Najdovska; S J Lin; J J Balic; E Okochi-Takada; P McGuirk; B Keogh; W McCormack; P S Bhathal; M Reilly; M Oshima; T Ushijima; P Tan; B J Jenkins
Journal:  Oncogene       Date:  2017-05-08       Impact factor: 9.867

3.  Hypermethylation of the interferon regulatory factor 5 promoter in Epstein-Barr virus-associated gastric carcinoma.

Authors:  Seung Myung Dong; Hyun Gyu Lee; Sung-Gyu Cho; Seung-Hyun Kwon; Heejei Yoon; Hyun-Jin Kwon; Ji Hae Lee; Hyemi Kim; Pil-Gu Park; Hoguen Kim; S Diane Hayward; Jeon Han Park; Jae Myun Lee
Journal:  J Microbiol       Date:  2015-01-04       Impact factor: 3.422

4.  TLR2 activation promotes tumour growth and associates with patient survival and chemotherapy response in pancreatic ductal adenocarcinoma.

Authors:  Joanne Lundy; Linden J Gearing; Hugh Gao; Alison C West; Louise McLeod; Virginie Deswaerte; Liang Yu; Sean Porazinski; Marina Pajic; Paul J Hertzog; Daniel Croagh; Brendan J Jenkins
Journal:  Oncogene       Date:  2021-08-16       Impact factor: 9.867

5.  TLR4 upregulates CBS expression through NF-κB activation in a rat model of irritable bowel syndrome with chronic visceral hypersensitivity.

Authors:  Bo Yuan; Wei-Hong Tang; Li-Juan Lu; Yuan Zhou; Hong-Yan Zhu; You-Lang Zhou; Hong-Hong Zhang; Chuang-Ying Hu; Guang-Yin Xu
Journal:  World J Gastroenterol       Date:  2015-07-28       Impact factor: 5.742

Review 6.  The microbiome and cancer.

Authors:  Robert F Schwabe; Christian Jobin
Journal:  Nat Rev Cancer       Date:  2013-10-17       Impact factor: 60.716

7.  miR-154 suppresses colorectal cancer cell growth and motility by targeting TLR2.

Authors:  Chaoguang Xin; Hao Zhang; Zanchao Liu
Journal:  Mol Cell Biochem       Date:  2013-11-16       Impact factor: 3.396

8.  Non-essential role for TLR2 and its signaling adaptor Mal/TIRAP in preserving normal lung architecture in mice.

Authors:  Saleela M Ruwanpura; Louise McLeod; Andrew R Lilja; Gavin Brooks; Lovisa F Dousha; Huei J Seow; Steven Bozinovski; Ross Vlahos; Paul J Hertzog; Gary P Anderson; Brendan J Jenkins
Journal:  PLoS One       Date:  2013-10-29       Impact factor: 3.240

Review 9.  Inflammation in gastric cancer: Interplay of the COX-2/prostaglandin E2 and Toll-like receptor/MyD88 pathways.

Authors:  Kanae Echizen; Osamu Hirose; Yusuke Maeda; Masanobu Oshima
Journal:  Cancer Sci       Date:  2016-03-18       Impact factor: 6.716

Review 10.  Application potential of toll-like receptors in cancer immunotherapy: Systematic review.

Authors:  Ming Shi; Xi Chen; Kangruo Ye; Yuanfei Yao; Yu Li
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.